Table 1.
Common AEs (≥ 2%) in the PARADIGM-HF trial during the double-blind treatment period [8]
| Preferred term, n (%) | Sacubitril/valsartan, n = 4203 | Enalapril, n = 4229 | Total, N = 8432 |
|---|---|---|---|
| At least 1 AE | 3419 (81.35) | 3503 (82.83) | 6922 (82.09) |
| Hypotension | 740 (17.61) | 506 (11.97) | 1246 (14.78) |
| Cardiac failure | 730 (17.37) | 832 (19.67) | 1562 (18.52) |
| Hyperkalemia | 488 (11.61) | 592 (14.00) | 1080 (12.81) |
| Renal impairment | 426 (10.14) | 487 (11.52) | 913 (10.83) |
| Cough | 369 (8.78) | 533 (12.60) | 902 (10.70) |
| Dizziness | 266 (6.33) | 206 (4.87) | 472 (5.60) |
| Atrial fibrillation | 251 (5.97) | 236 (5.58) | 487 (5.78) |
| Pneumonia | 227 (5.40) | 237 (5.60) | 464 (5.50) |
| Peripheral edema | 215 (5.12) | 213 (5.04) | 428 (5.08) |
Used with permission from [8]. Copyright 2014: Massachusetts Medical Society
AE adverse event, PARADIGM-HF Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure